ImmuONE provides innovative respiratory in vitro cell culture products and contract research services for inhalation safety testing. Our focus is supporting companies and researchers to understand the interaction and safety implications of inhaled products with immune cells in the airways.
We use state-of-the-art techniques within our in-house service portfolio to address unmet needs within inhalation assessment. Our specialist team of in vitro scientists work closely with customers to develop assays and strategies that solve your toxicity and translational needs.
Standard portfolio Advanced multi-metric assessments Novel immune-competent products Along with the air we inhale, each breath also contains a cocktail of chemicals and particles from our environment. The immune system in the lungs interacts with these chemicals and determines the body’s response to them. Despite respiratory immunology being a key aspect of inhaled product safety, in vitro models and assays to mimic these responses was an unmet need and animal experiments have traditionally been heavily relied upon to provide this information.
Since 2013, researchers at ImmuONE have been working to provides a solution to this problem.
We are experts in the lung’s immune system – in particular, the alveolar macrophages which are the first to respond when a chemical enters the respiratory system. Our services, products and experts enable you to understand, in detail how alveolar macrophages respond to inhaled chemicals/particulates and support classification of the response as being adaptive or adverse.
Our services, products and experts enable you to understand, in detail, how alveolar macrophages respond to inhaled chemicals/particulates and support classification of the response as being adaptive or adverse.
Our unique in vitro models and multi-endpoint assessments deliver results spanning morphology, function and biochemistry to provide companies with clarity on the human health impact of their products. We provide a cost-effective, multi-endpoint alternative which is more human-relevant and reduces animal testing, exploring various interpretations of a read-out.
We carry out a wide variety of in vitro services in-house, with a specialisation in alveolar high content imaging assays. Our morph_ONE™ assay combines detailed cell morphology with cell health and biochemical readouts to help classify the mechanism of ‘foamy’, highly vacuolated macrophages to support safety assessment. Our two novel products – ImmuPHAGE™ and ImmuLUNG™ – provide in-depth analysis of macrophage responses in the lungs and epithelial tissue of the alveoli.
Understanding the inflammatory response of the airways to inhaled substances is paramount to assessing the long-term adverse effects on lung health. Many inhaled substances reach the small or distal airways, and it is in this region of the lung where alveolar macrophages are the first responders to these substances and play a pivotal role in homeostasis and regulating inflammation. Therefore, to ensure a comprehensive safety of inhaled products, it’s imperative to employ immune-competent models that capture the nuanced responses of alveolar macrophages.
At ImmuONE, we specialise in alveolar macrophage models and responses. Our services, products and experts enable you to understand, in detail how alveolar macrophages respond to inhaled chemicals/particulates and support classification of the response as being adaptive or adverse.
Gender equality in the biotech industry has come a long way in recent years. In the UK, the US and Europe, women now make up between 40-50% of the biotech workforce, which is a higher percentage than in other STEM fields, such as engineering and the physical sciences.
Brendon Ghiot, our Senior Scientist at ImmuONE, joins us for a coffee to share his diverse journey from working in cellular biology to pioneering in CAR-T therapy for cancer treatment. Brendon tells us what drives his interest in developing new technologies at ImmuONE, particularly in animal-free inhalation toxicity testing.
Gender equality in the biotech industry has come a long way in recent years. In the UK, the US and Europe, women now make up between 40-50% of the biotech workforce, which is a higher percentage than in other STEM fields, such as engineering and the physical sciences.